ID: ALA4643230

Max Phase: Preclinical

Molecular Formula: C31H38O6

Molecular Weight: 506.64

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C[C@@H]1CC[C@@H]2[C@@H]1[C@H](OC(=O)c1ccc3ccccc3c1)[C@]1(C3CCCCC3)C[C@@H](OC(=O)CO)[C@@]2(C)O1

Standard InChI:  InChI=1S/C31H38O6/c1-19-12-15-24-27(19)28(36-29(34)22-14-13-20-8-6-7-9-21(20)16-22)31(23-10-4-3-5-11-23)17-25(30(24,2)37-31)35-26(33)18-32/h6-9,13-14,16,19,23-25,27-28,32H,3-5,10-12,15,17-18H2,1-2H3/t19-,24-,25-,27-,28+,30+,31-/m1/s1

Standard InChI Key:  IDLVJHYEYXKECJ-CVLVEMSBSA-N

Associated Targets(Human)

A498 42825 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

UO-31 46270 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RXF 393 41971 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

TRPC4/TRPC1 20 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Short transient receptor potential channel 5 300 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 506.64Molecular Weight (Monoisotopic): 506.2668AlogP: 5.44#Rotatable Bonds: 5
Polar Surface Area: 82.06Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.13CX Basic pKa: CX LogP: 5.70CX LogD: 5.70
Aromatic Rings: 2Heavy Atoms: 37QED Weighted: 0.54Np Likeness Score: 1.80

References

1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA..  (2020)  Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.,  11  (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186]

Source